These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 30168265

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [Abstract] [Full Text] [Related]

  • 5. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 6. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.
    PLoS One; 2017 Jul; 12(4):e0175207. PubMed ID: 28448562
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N.
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [Abstract] [Full Text] [Related]

  • 12. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R.
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [Abstract] [Full Text] [Related]

  • 13. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.
    Arthritis Res Ther; 2019 Apr 11; 21(1):91. PubMed ID: 30971306
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.
    Arthritis Res Ther; 2010 Apr 11; 12(3):R117. PubMed ID: 20553600
    [Abstract] [Full Text] [Related]

  • 15. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
    Mori A, Saito T, Takahashi M, Shibata M, Tsuji G, Hatachi S, Takahashi S, Kumagai S.
    PLoS One; 2020 Apr 11; 15(12):e0243729. PubMed ID: 33315881
    [Abstract] [Full Text] [Related]

  • 16. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP, Louzada-Junior P, Titton DC, Zandonade E, Ranza R, Laurindo I, Peçanha P, Ranzolin A, Hayata AL, Duarte A, Silveira IG, Costa I, Macieira JC, Guedes-Barbosa LS, Bertolo MB, Sauma MF, Silva MB, Freire M, Scheinberg MA, Fernandes V, Bianchi W, Miranda JR, Pinheiro GR, Carvalho HM, Brenol CV, Pereira IA, de Castro GR, de Morais JC, Oliveira SK, de Abreu MM, Toledo RA, Pinheiro MM, Vieira WP, Valim V, BIOBADABRASIL.
    Clin Rheumatol; 2015 May 11; 34(5):921-7. PubMed ID: 25851594
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings.
    Iannone F, Lopriore S, Bucci R, Lopalco G, Chialà A, Cantarini L, Lapadula G.
    J Rheumatol; 2016 May 11; 43(5):911-7. PubMed ID: 26980583
    [Abstract] [Full Text] [Related]

  • 19. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
    Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Harrison DJ, Joseph GJ, Sauer BC.
    J Rheumatol; 2014 Oct 11; 41(10):1935-43. PubMed ID: 25128516
    [Abstract] [Full Text] [Related]

  • 20. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
    Soubrier M, Pereira B, Frayssac T, Abdi D, Couderc M, Daron C, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ.
    Clin Exp Rheumatol; 2016 Oct 11; 34(6):1059-1064. PubMed ID: 27607233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.